摘要
目的建立一种以活化吖啶酯标记抗人平足蛋白抗体为标记物检测人血清中平足蛋白(PDPN)的磁微粒化学发光免疫检测方法并进行在乳腺癌相关疾病方面的临床应用验证。方法以包被链酶亲和素磁微粒-活化生物素标记抗人平足蛋白抗体为固相分离载体,生物素标记一株鼠抗人平足蛋白单克隆抗体,吖啶酯标记另一株鼠抗人平足蛋白单克隆抗体,建立人血清样本中PDPN定量免疫分析方法。结果在线性范围1.00~800.00ng/mL内,相关系数r为0.9990,检出限为0.52ng/mL;批内重复性不超过5.0%,批间差不超过10.0%;正常参考区间为小于4.50ng/mL;测定乳腺癌临床样本,特异性为88%和灵敏度为87%。结论建立了定量检测人血清中PDPN水平的化学发光免疫分析法,对乳腺癌的发生发展起了辅助诊断作用。
Objective To develop a magnetic particle chemiluminescence immunoassay for podoplanin in serum with acridine ester as the marker and to conduct a preliminary clinical verification.Methods In conjunction with a streptavidin coated magnetic particle separation system,one anti-PDPN mouse monoclonal antibody was biotinylated and another anti-PDPN mouse monoclonal antibody was acridine ester labeled.Through this pipeline,a sandwich immunoassay for human serum PDPN quantitative detection was established.Results LoD of this assay was below 0.52ng/mL,while the within-lot and total precision were less than 5.0%and 10.0%,the linear range was 1.00-800.00ng/mL,and the reference interval was 4.50ng/mL.The specification was 88%and sensitivity was 87%for samples of breast cancer.Conclusion In the current study,a chemiluminescence immunoassay is established for the quantitative determination of acridine ester as marker of PDPN serum,which is useful the breast cancer clinical diagnosis.
作者
丁兴龙
李洪春
DING Xinglong;LI Hongchun(The Second Affiliated Hospital of Xuzhou Medical University,Xuzhou 2210006,China;Xuzhou Medical University,Xuzhou 2210000,China)
出处
《标记免疫分析与临床》
CAS
2023年第6期1047-1051,共5页
Labeled Immunoassays and Clinical Medicine
